Neurology

Neu Health Launches in U.S., Supported by FDA Clearance for Parkinson’s Tremor Measurement

Delivering precision neurology via smartphone, Neu Health is built on the Oxford Discovery Cohort, one of the world's largest longitudinal…

5 months ago

Creyos Featured in Alzheimer’s Research at AAIC 2025

Findings from Western University, QIMR Berghofer, and Rotman Research Institute underscore the power of Creyos in detecting early risk, validating digital…

5 months ago

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs…

5 months ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA…

5 months ago

Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke

The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of…

5 months ago

Qynapse Releases Data Highlighting the Accuracy of QyScore® and Predictive performance of QyPredict® for Disease Progression in preclinical Alzheimer’s Disease

TORONTO, July 28, 2025 /PRNewswire/ -- Qynapse, a technology company using AI to enhance the quantification and predictive capabilities of imaging…

5 months ago

Siemens Healthineers Receives Frost & Sullivan’s 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications

Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions SAN ANTONIO, July 28, 2025…

5 months ago

Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference

Analysis of first-in-class CNS-101 study validates that at-home endpoints showed greater separation with Alzheimer's pathology (pTau217) than the benchmark endpoint…

5 months ago